Black Health
Integrase strand transfer inhibitor (INSTI) + NRTIs — single-tablet HIV regimen HIV-1 treatment (initial and switch)

Bictegravir/Tenofovir Alafenamide/Emtricitabine (Biktarvy) and Black patients

Brand names: Biktarvy

Last reviewed: Sources checked:

What Bictegravir/Tenofovir Alafenamide/Emtricitabine does

Biktarvy is a once-daily single-tablet regimen combining bictegravir (integrase inhibitor) with tenofovir alafenamide and emtricitabine. It is widely used as first-line HIV treatment and for switches from older regimens because of its efficacy, durability, and low pill burden.

What the evidence says for Black patients

Biktarvy's pivotal trials (Sax et al., Lancet 2017;390:2073–82; Gallant et al., Lancet HIV 2017;4:e154–60) enrolled clinically meaningful proportions of Black participants and showed consistent viral suppression and tolerability. The DHHS Adult and Adolescent ARV Guidelines position it as a recommended first-line regimen.

Equity points:

  • Integrase inhibitor-associated weight gain is a real signal, affecting Black women disproportionately. The NAMSAL and ADVANCE trials (both conducted in sub-Saharan Africa with mostly Black participants) showed 4–6 kg greater weight gain at 96 weeks with dolutegravir/TAF regimens compared to dolutegravir/TDF or efavirenz — with Black women most affected. Biktarvy shares this signal (bictegravir is closely related to dolutegravir; TAF is a contributor).
  • Ryan White Program covers Biktarvy for uninsured and underinsured patients in the US — a critical access tool given Biktarvy's commercial list price of $3,800+/month.
  • U=U (Undetectable = Untransmittable) messaging is especially important for Black patients facing HIV stigma; PARTNER and HPTN 052 established that sustained viral suppression prevents sexual transmission.

Common alternatives

Dolutegravir + TDF/FTC (Tivicay + Truvada) — generic components available, lowest-cost option. Dolutegravir + TAF/FTC (Dovato). Dolutegravir/lamivudine (Dovato) — 2-drug regimen for selected patients.

Side effects

  • Headache, GI upset (early)
  • Weight gain
  • Insomnia, depression (INSTI class effects)
  • Small creatinine rise (cobicistat-independent — just a transporter effect)
  • Rare hypersensitivity
  • Drug-drug interactions with antacids, some anti-seizure drugs

Factors that affect adherence

Once daily with or without food. Do not take with aluminum/magnesium antacids within 2 hours. Biktarvy without the Ryan White / ADAP safety net is expensive; advocate with clinician and social worker to make sure coverage is active and stable.

Questions to ask your doctor

Bring this list to your next appointment.

  • Given the weight-gain signal with integrase inhibitors + TAF, is Biktarvy the right choice for me versus a TDF-containing regimen?
  • Am I on Ryan White or ADAP coverage, and is my coverage uninterrupted?
  • What's my viral load goal, and when do we recheck?
  • Am I counseling partners on U=U?

References

  1. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection (GS-US-380-1490). Lancet. 2017;390:2073–2082.
  2. Sower L, Molina JM, Orkin C, et al. NAMSAL and ADVANCE trials — weight gain with integrase inhibitors. Multiple analyses, IAS 2019–2022 conferences.
  3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
  4. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER). Lancet. 2019;393:2428–2438.
  5. U.S. Food and Drug Administration. Biktarvy label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.